chufangao/CTO huggingface dataset:
Clinical trial NCT03772587: A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
Official title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
Sponsor: Momenta Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 68.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-04-10
Primary completion date: 2020-06-25
Completion date: 2020-06-25
Baseline population: Intent-to-treat (ITT) population included all randomized participants.
Limitations and caveats: Limitations to this study include the small sample sizes of each treatment arm and the study activity disruption due to the COVID-19 pandemic, especially the missed Quantitative Myasthenia Gravis (QMG) assessments which hampered the analysis of the endpoint.
Plan to share individual participant data: NO
Clinical trial NCT03983980: Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)
Official title: A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults
Sponsor: Dermavant Sciences, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 515.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-06
Primary completion date: 2020-05-13
Completion date: 2020-05-29
Plan to share individual participant data: NO
Clinical trial NCT04841577: A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above
Official title: A Phase 3, Open-label, Randomized, Controlled, Multi-country Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co-administered With FLU-QIV Vaccine in Adults Aged 60 Years and Above
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 976.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-27
Primary completion date: 2021-09-22
Completion date: 2022-02-08
Plan to share individual participant data: YES
IPD sharing description: GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
IPD time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Clinical trial NCT03817190: Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis
Official title: A Randomised, Double-blind, Placebo-controlled, Study to Assess the Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis
Sponsor: DS Biopharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Based on Interim Analysis results
Enrollment: 219.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-19
Primary completion date: 2020-09-03
Completion date: 2020-09-03
Baseline population: The Randomised Set consists of all patients who are randomised to the study.
Limitations and caveats: The decision to terminate the study prematurely was based on the results from an interim analysis.
Clinical trial NCT04992065: A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
Official title: Dose Response and Safety of an Oral PCSK9i, NNC0385-0434, in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk on Maximally Tolerated Statin Dose and Other Lipid-lowering Therapy Requiring Further LDL-C Reduction
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 255.0 (ACTUAL)
Number of arms: 7.0
Start date: 2021-08-03
Primary completion date: 2022-04-26
Completion date: 2022-06-20
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT02601014: Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
Official title: Biomarker-Driven Phase-2 Study of Combined Immune Checkpoint Blockade for AR-V7-Expressing Metastatic Castration-Resistant Prostate Cancer (STARVE-PC)
Acronym: STARVE-PC
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 32.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-03-15
Primary completion date: 2020-12-03
Completion date: 2021-10-06
Plan to share individual participant data: NO
Clinical trial NCT05418101: A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)
Official title: A Phase 1, First-in-human, 2-part Study (Part 1 is a Single Ascending Dose in Healthy Participants; Part 2 is a Multiple Ascending Dose Study in Participants With Autoimmune Disease) to Evaluate the Safety, PD and PK of VIS171
Sponsor: Visterra, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study terminated due to internal strategy change due to changes in risk-benefit ratio
Enrollment: 61.0 (ACTUAL)
Number of arms: 8.0
Start date: 2022-04-28
Primary completion date: 2024-02-15
Completion date: 2024-02-15
Plan to share individual participant data: NO
Clinical trial NCT03654040: Liver Transplantation With Tregs at UCSF
Official title: A Phase I/II Drug Withdrawal Study of Alloantigen-Specific Tregs in Liver Transplantation
Acronym: LITTMUS-UCSF
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was terminated by the Sponsor prior to any participants receiving the investigational product.
Enrollment: 42.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-04-22
Primary completion date: 2023-03-06
Completion date: 2023-03-06
Baseline population: Transplanted participants who enrolled but did not receive arTregs and living donors of the prospective transplant recipient who consented and enrolled into the study
Limitations and caveats: The study was terminated by the sponsor in February 2023 prior to any participant receiving the investigational product, arTregs. The study's low enrollment would not allow for study completion within the necessary timeframe.
Plan to share individual participant data: YES
IPD sharing description: The plan is to share data upon completion of the study in ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
IPD time frame: The aim is to share data available to the public within 24 months upon completion of the study.
IPD access criteria: ImmPort public data access.
Clinical trial NCT01564537: A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Official title: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 722.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-08-01
Primary completion date: 2014-10-01
Completion date: 2022-02-08
Baseline population: Intent-to-Treat (ITT) population was defined as all randomized participants.
Clinical trial NCT03575208: Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B
Official title: Use of Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in Patients With Chronic Hepatitis B
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Slow/Insufficient accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-13
Primary completion date: 2022-03-29
Completion date: 2022-03-29
Clinical trial NCT04768855: A Study of LY3540378 in Healthy Participants
Official title: A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3540378 in Healthy Participants
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 134.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-03-17
Primary completion date: 2022-05-30
Completion date: 2022-05-30
Plan to share individual participant data: NO
Clinical trial NCT04109144: Fresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis
Official title: Fresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis
Sponsor: Montefiore Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: PI confirmed that while coordination and planning was conducted upon IRB approval, no participants were enrolled into the study
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-11
Primary completion date: 2023-07-31
Completion date: 2023-07-31
Plan to share individual participant data: NO
IPD sharing description: Data collected during the study will only be shared with researchers that have been IRB approved as key-personnel on the study protocol.
Clinical trial NCT04216784: Comparison of Diuretic Effect With Furosemide Alone Versus the Combination of Furosemide and Albumin in Cirrhotic Patients
Official title: Comparison of Diuretic Effect With Furosemide Alone Versus the Combination of Furosemide and Albumin in Cirrhotic Patients
Sponsor: Rush University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The study halted prematurely due to staffing.
Enrollment: 21.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-19
Primary completion date: 2023-12-30
Completion date: 2024-04-01
Plan to share individual participant data: NO
Clinical trial NCT04540419: Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19
Official title: Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group Study Evaluating Efficacy, Reactogenicity and Safety of Recombinant Vaccine Ad5-nCoV Against Novel Coronavirus Infection in Adult Volunteers
Sponsor: NPO Petrovax (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 500.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-11
Primary completion date: 2021-06-19
Completion date: 2021-07-30
Clinical trial NCT05172115: Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE
Official title: Catheter-Directed Thrombolysis Versus ANticoagulation Monotherapy in Patients With Acute Intermediate-High Risk PulmonarY Embolism: The CANARY Randomized Clinical Trial
Acronym: CANARY
Sponsor: Rajaie Cardiovascular Medical and Research Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Due to the COVID-19 pandemic
Enrollment: 94.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-22
Primary completion date: 2020-02-02
Completion date: 2020-05-02
Plan to share individual participant data: NO
IPD sharing description: Data will become available to interested investigators upon submitting a reasonable research request, approved by the Steering Committee of the trial.
Clinical trial NCT03571828: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Official title: A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With Relapsed / Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Amgen decided to discontinue study because of a business decision and not because of safety reasons
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-29
Primary completion date: 2022-01-12
Completion date: 2022-01-12
Baseline population: Safety Analysis Set: All participants who received at least one dose of investigational product.
Limitations and caveats: Amgen decided not to continue development of AMG 562 because of a business decision and not because of safety reasons. No conclusions can be drawn due to the small sample size of this study.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Clinical trial NCT01609790: Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Official title: Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 137.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-06-04
Primary completion date: 2015-10-02
Completion date: 2022-05-20
Baseline population: All eligible patients.
Clinical trial NCT03846427: Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma
Official title: A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Acronym: MAGNOLIA
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 68.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-19
Primary completion date: 2022-05-04
Completion date: 2022-05-04
Plan to share individual participant data: YES
Clinical trial NCT01578239: A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Official title: A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Acronym: NETTER-1
Sponsor: Advanced Accelerator Applications (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 231.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-09-06
Primary completion date: 2015-07-31
Completion date: 2021-01-18
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT04273191: A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)
Official title: An Evaluation of Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO
Sponsor: Sage Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Sage Therapeutics has decided not to proceed with this study at this time
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-02-29
Primary completion date: 2021-08-31
Completion date: 2021-08-31
Plan to share individual participant data: NO
IPD sharing description: Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.
Clinical trial NCT03878927: CPX-351+GO in Subjects 55 Years Old, or Older, With AML
Official title: Phase I Trial, With an Expansion Cohort, of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Combination With Gemtuzumab in Subjects With Acute Myeloid Leukemia >55 Years of Age Who Have Not Been Treated With Intensive Chemotherapy
Acronym: CPX GO
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Dose limiting toxicities.
Enrollment: 11.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-08-23
Primary completion date: 2022-08-15
Completion date: 2022-09-01
Plan to share individual participant data: NO
Clinical trial NCT04442126: A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Official title: A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors
Sponsor: Numab Therapeutics AG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
Enrollment: 52.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-19
Primary completion date: 2024-02-06
Completion date: 2024-02-06
Clinical trial NCT04536350: Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS
Official title: Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS: A Randomized, Placebo Controlled, Multicenter Trial
Sponsor: Cantonal Hosptal, Baselland (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Difficulties recruiting participants for the Aviptadil study as there are nowadays very few hospitalized COVID patients. Continuous screening has been carried out but none of the patients met the eligibility criteria for the study.
Enrollment: 83.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-18
Primary completion date: 2023-06-14
Completion date: 2023-06-14
Plan to share individual participant data: NO
Clinical trial NCT01515748: Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer
Official title: A Phase III, Open-labelled, Randomised Study of Neoadjuvant Docetaxel+Oxaliplatin+S-1 (DOS) + Surgery + Adjuvant S-1 Versus Surgery + Adjuvant S-1 in Patients With Resectable Advanced Gastric Cancer
Acronym: PRODIGY
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 530.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-12-30
Primary completion date: 2019-01-21
Completion date: 2021-12-13
Baseline population: Analysis was performed on Intent-to-Treat (ITT) population which included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT04531397: Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease
Official title: Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease : a Prospective, Randomized, Placebo-controlled Trial
Sponsor: Children's Hospital of Fudan University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-01
Primary completion date: 2022-06-01
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT02794285: Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Official title: A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.
Acronym: TULIP SLE LTE
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 559.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-30
Primary completion date: 2021-12-21
Completion date: 2021-12-21
Baseline population: Full Analysis Set (FAS) - LTE Study: consisted of all participants who were randomised and received at least 1 dose of investigational product in the LTE Study.
Clinical trial NCT03598270: Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer
Official title: A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months
Acronym: ANITA
Sponsor: Grupo Español de Investigación en Cáncer de Ovario (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 417.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-21
Primary completion date: 2024-08-05
Completion date: 2024-08-05